JP2011515397A5 - - Google Patents

Download PDF

Info

Publication number
JP2011515397A5
JP2011515397A5 JP2011500801A JP2011500801A JP2011515397A5 JP 2011515397 A5 JP2011515397 A5 JP 2011515397A5 JP 2011500801 A JP2011500801 A JP 2011500801A JP 2011500801 A JP2011500801 A JP 2011500801A JP 2011515397 A5 JP2011515397 A5 JP 2011515397A5
Authority
JP
Japan
Prior art keywords
compound
lower alkyl
hydrogen
optionally substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011500801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011515397A (ja
JP5628145B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/001691 external-priority patent/WO2009117097A1/en
Publication of JP2011515397A publication Critical patent/JP2011515397A/ja
Publication of JP2011515397A5 publication Critical patent/JP2011515397A5/ja
Application granted granted Critical
Publication of JP5628145B2 publication Critical patent/JP5628145B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011500801A 2008-03-19 2009-03-18 新規チロシンキナーゼ阻害剤 Expired - Fee Related JP5628145B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3803208P 2008-03-19 2008-03-19
US61/038,032 2008-03-19
PCT/US2009/001691 WO2009117097A1 (en) 2008-03-19 2009-03-18 Novel tyrosine kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013006922A Division JP2013082744A (ja) 2008-03-19 2013-01-18 新規チロシンキナーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2011515397A JP2011515397A (ja) 2011-05-19
JP2011515397A5 true JP2011515397A5 (US20040106767A1-20040603-C00005.png) 2012-05-10
JP5628145B2 JP5628145B2 (ja) 2014-11-19

Family

ID=40814009

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011500801A Expired - Fee Related JP5628145B2 (ja) 2008-03-19 2009-03-18 新規チロシンキナーゼ阻害剤
JP2013006922A Pending JP2013082744A (ja) 2008-03-19 2013-01-18 新規チロシンキナーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013006922A Pending JP2013082744A (ja) 2008-03-19 2013-01-18 新規チロシンキナーゼ阻害剤

Country Status (9)

Country Link
US (1) US8815906B2 (US20040106767A1-20040603-C00005.png)
EP (2) EP2262807B1 (US20040106767A1-20040603-C00005.png)
JP (2) JP5628145B2 (US20040106767A1-20040603-C00005.png)
CN (1) CN102036990B (US20040106767A1-20040603-C00005.png)
AU (1) AU2009226153B2 (US20040106767A1-20040603-C00005.png)
CA (1) CA2718872C (US20040106767A1-20040603-C00005.png)
DK (1) DK2262807T3 (US20040106767A1-20040603-C00005.png)
MX (1) MX2010010272A (US20040106767A1-20040603-C00005.png)
WO (1) WO2009117097A1 (US20040106767A1-20040603-C00005.png)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249147B2 (en) 2008-03-19 2016-02-02 Chembridge Corporation Tyrosine kinase inhibitors
WO2009117097A1 (en) * 2008-03-19 2009-09-24 Chembridge Corporation Novel tyrosine kinase inhibitors
US8822500B2 (en) 2008-03-19 2014-09-02 Chembridge Corporation Tyrosine kinase inhibitors
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
PL2496567T3 (pl) 2009-11-05 2018-01-31 Rhizen Pharmaceuticals S A Nowe benzopiranowe modulatory kinazy
CR20170098A (es) 2010-05-20 2017-07-17 Array Biopharma Inc Compuestos macrociclicos como inhibidores de quinasa trk
SG194718A1 (en) 2011-05-04 2013-12-30 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinases
MX2014005632A (es) * 2011-11-14 2014-10-17 Tesaro Inc Modulacion de ciertas cinasas de tirosina.
MX2014012992A (es) 2012-04-24 2015-08-14 Chugai Pharmaceutical Co Ltd Derivado de quinazolindiona.
JP6177768B2 (ja) 2012-04-24 2017-08-09 中外製薬株式会社 ベンズアミド誘導体
ES2647416T3 (es) 2012-07-04 2017-12-21 Rhizen Pharmaceuticals S.A. Inhibidores de PI3K delta selectivos
JP2016510751A (ja) 2013-03-06 2016-04-11 ジェネンテック, インコーポレイテッド 抗がん剤耐性を治療及び予防する方法
CN104109168B (zh) * 2013-04-20 2017-02-15 山东轩竹医药科技有限公司 四并环激酶抑制剂
TW201524990A (zh) 2013-10-11 2015-07-01 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
WO2015060373A1 (ja) 2013-10-23 2015-04-30 中外製薬株式会社 キナゾリノンおよびイソキノリノン誘導体
CN116509866A (zh) * 2014-02-04 2023-08-01 安斯泰来制药株式会社 二氨基杂环甲酰胺化合物的用途
TWI680977B (zh) * 2014-04-17 2020-01-01 美商安美基公司 c-Met抑制劑之多晶形式及共晶
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
BR112017019305A2 (pt) * 2015-03-10 2018-05-08 Aurigene Discovery Technologies Limited compostos cíclicos terapêuticos como imunomoduladores
JP2018521988A (ja) 2015-06-16 2018-08-09 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. ピペリジン誘導体およびその製造方法および医薬用途
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
CN108602890A (zh) 2015-12-11 2018-09-28 瑞泽恩制药公司 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
CA3049136C (en) 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TW202410896A (zh) 2017-10-10 2024-03-16 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
US11236103B2 (en) 2018-07-27 2022-02-01 Biotheryx, Inc. Bifunctional compounds
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Retキナーゼ阻害剤としての縮合複素環式化合物
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4143329A4 (en) 2020-04-28 2024-10-16 Anwita Biosciences Inc INTERLEUKIN-2 POLYPEPTIDES AND FUSION PROTEINS THEREOF, AS WELL AS THEIR PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
EP0600830A1 (de) * 1992-11-27 1994-06-08 Ciba-Geigy Ag Substituierte Derivate von Diaminophthalimid als Protein-Tyrosin-Kinase-Hemmer
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
EP1581539A4 (en) 2003-01-03 2007-09-19 Bristol Myers Squibb Co NEW TYROSINE KINASE HEMMER
MXPA05011726A (es) 2003-04-28 2006-01-23 Tibotec Pharm Ltd Inhibidores de intregrasa de virus de inmunodeficiencia humana.
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20060235013A1 (en) * 2005-04-14 2006-10-19 Guy Georges Tricyclic azole derivatives
CN101208093A (zh) * 2005-04-27 2008-06-25 阿斯利康(瑞典)有限公司 吡唑-嘧啶衍生物在治疗疼痛中的用途
US20080062003A1 (en) * 2006-08-07 2008-03-13 Christian Paetz Wireless controllable power control device molded into a power cable
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
WO2008022747A1 (en) * 2006-08-21 2008-02-28 F. Hoffmann-La Roche Ag Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
WO2009117097A1 (en) * 2008-03-19 2009-09-24 Chembridge Corporation Novel tyrosine kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2011515397A5 (US20040106767A1-20040603-C00005.png)
JP2010241830A5 (US20040106767A1-20040603-C00005.png)
JP2016501221A5 (US20040106767A1-20040603-C00005.png)
JP2016513137A5 (US20040106767A1-20040603-C00005.png)
RU2015125307A (ru) Комбинированная терапия
RU2017145026A (ru) Соединение, ингибирующее brk
JP2017528498A5 (US20040106767A1-20040603-C00005.png)
CA3094449A1 (en) Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
JP2020514409A5 (US20040106767A1-20040603-C00005.png)
JP2008528468A5 (US20040106767A1-20040603-C00005.png)
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
JP2010502651A5 (US20040106767A1-20040603-C00005.png)
JP2016520618A5 (US20040106767A1-20040603-C00005.png)
RU2015104537A (ru) Способы лечения стромальных опухолей желудочно-кишечного тракта
RU2014120792A (ru) Способ лечения стромальных опухолей желудочно-кишечного тракта
JP2015524472A5 (US20040106767A1-20040603-C00005.png)
JP2014503567A5 (US20040106767A1-20040603-C00005.png)
JP2014532647A5 (US20040106767A1-20040603-C00005.png)
JP6620338B2 (ja) 低用量ナルトレキソンによるがん細胞の準備刺激
JP2014505107A5 (US20040106767A1-20040603-C00005.png)
JP2017532360A5 (US20040106767A1-20040603-C00005.png)
JP2017526662A5 (US20040106767A1-20040603-C00005.png)
EA201200472A1 (ru) Сульфонамиды в качестве ингибиторов белков семейства bcl-2, предназначенные для лечения рака
TN2012000110A1 (en) N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
CA2922684A1 (en) Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases